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Background—A systematic assessment of potential disease-modifying compounds for 
Parkinson's disease concluded that pioglitazone could hold promise for the treatment of patients 
with this disease. We assessed the effect of pioglitazone on the progression of Parkinson's disease 
in a multicentre, double-blind, placebo-controlled, futility clinical trial.
Methods—Participants with the diagnosis of early Parkinson's disease on a stable regimen of 1 
mg/day rasagiline or 10 mg/day selegiline were randomly assigned (1:1:1) to 15 mg/day 
pioglitazone, 45 mg/day pioglitazone, or placebo. Investigators were masked to the treatment 
assignment. Only the statistical centre and the central pharmacy knew the treatment name 
associated with the randomisation number. The primary outcome was the change in the total 
Unified Parkinson's Disease Rating Scale (UPDRS) score between the baseline and 44 weeks, 
analysed by intention to treat. The primary null hypothesis for each dose group was that the mean 
change in UPDRS was 3 points less than the mean change in the placebo group. The alternative 
hypothesis (of futility) was that pioglitazone is not meaningfully different from placebo. We 
rejected the null if there was significant evidence of futility at the one-sided alpha level of 0.10. 
The study is registered at ClinicalTrials.gov, number NCT01280123.
Findings—210 patients from 35 sites in the USA were enrolled between May 10, 2011, and July 
31, 2013. The primary analysis included 72 patients in the 15 mg group, 67 in the 45 mg group, 
and 71 in the placebo group. The mean total UPDRS change at 44 weeks was 4.42 (95% CI 2.55–
6.28) for 15 mg pioglitazone, 5.13 (95% CI 3.17–7.08) for 45 mg pioglitazone, and 6.25 (95% CI 
4.35–8.15) for placebo (higher change scores are worse). The mean difference between the 15 mg 
and placebo groups was −1.83 (80% CI −3.56 to −0.10) and the null hypothesis could not be 
rejected (p=0.19). The mean difference between the 45 mg and placebo groups was −1.12 (80% CI 
−2.93 to 0.69) and the null hypothesis was rejected in favour of futility (p=0.09). Planned 
sensitivity analyses of the primary outcome, using last value carried forward (LVCF) to handle 
missing data and using the completers' only sample, suggested that the 15 mg dose is also futile 
(p=0.09 for LVCF, p=0.09 for completers) but failed to reject the null hypothesis for the 45 mg 
dose (p=0.12 for LVCF, p=0.19 for completers). Six serious adverse events occurred in the 15 mg 
group, nine in the 45 mg group, and three in the placebo group; none were thought to be definitely 
or probably related to the study interventions.
Interpretation—These findings suggest that pioglitazone at the doses studied here is unlikely to 
modify progression in early Parkinson's disease. Further study of pioglitazone in a larger trial in 
patients with Parkinson's disease is not recommended.
Funding—National Institute of Neurological Disorders and Stroke.
Introduction
Parkinson's disease affects nearly 1% of the population aged over 60 years.1 Despite 
effective therapies to treat symptoms of Parkinson's disease and many clinical trials,2,3 no 
interventions have been proven to slow progression of disability (ie, achieve disease 
modification). In 2001, the National Institute of Neurological Disorders and Stroke (NINDS) 
created the Neuroprotection Exploratory Trials of Parkinson's Disease (NET-PD) 
programme to assess therapies to slow progression of disability in Parkinson's disease (based 
on recommendations by the Committee to Identify Neuroprotective Agents in Parkinson's 
[CINAPS]).4 Pioglitazone was selected through a rigorous systematic review of agents to be 
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tested by the NET-PD network as a potential disease-modifying agent in early Parkinson's 
disease.4 Pioglitazone is approved by the US Food and Drug Administration (FDA) for the 
treatment of type 2 diabetes and acts to reduce insulin resistance; it belongs to the class of 
thiazolidinediones, the peroxisome proliferator-activated receptor γ (PPAR-γ) agonists. 
Preclinical and early clinical evidence suggests that thiazolidinediones might have 
neuroprotective effects in Parkinson's disease and other neurodegenerative diseases.5–9 
Although the precise mechanisms through which PPAR-γ agonists might provide 
neuroprotection are still unclear, they inhibit the activation of microglia and astrocytes and 
production of pro-inflammatory cytokines and nitric oxide.10 PPAR-γ coactivator 1-α 
(PGC-1α) is a transcriptional coactivator that controls mitochondrial biogenesis and 
oxidative stress.11 Preclinical data in rodent and primate Parkinson's disease models showed 
good CNS penetration of pioglitazone and neuroprotective effects at a dose in animals that is 
the equivalent of the FDA-approved dose for use in human beings.11–14
Our primary objective was to assess the effect of pioglitazone on the progression of 
Parkinson's disease to establish whether further study of this agent is futile. The study 
known as FS-ZONE was based on the futility design (non-superiority) that has been used in 
two phase 2 studies done by NET-PD.15,16 Futility studies are phase 2 clinical trials 
designed to identify and eliminate compounds that have low likelihood of being efficacious 
in definitive efficacy studies by comparing the primary outcome measure in the treatment 
group versus placebo to a prespecified threshold value.17,18 Progression of Parkinson's 
disease was measured by change in total Unified Parkinson Disease Rating Scale score 
(UPDRS parts I–III)19 between the baseline and the 44 week visit. If both doses of 
pioglitazone were non-futile, the plan was to select the dose that was associated with the 
smallest (better) change of the UPDRS score. A final decision about whether to continue 
studying that dose had also to take into account tolerability, toxicity, and other safety issues.
Methods
Study design and participants
The trial was a multicentre, three-group, double-blind, placebo-controlled parallel group 
study. The trial was organised by the Clinical Trials Coordination Center (CTCC) at the 
University of Rochester, NY, USA, the Statistical Center at the Division of Biostatistics, 
University of Texas School of Public Health, TX, USA, and the NINDS.
Participants were men and women aged 30 years or older with idiopathic Parkinson's disease 
based on UK Brain Bank diagnostic criteria20 diagnosed within 5 years of enrolment with a 
Hoehn and Yahr score of 2 or less. Participants had to be on a stable dosage of rasagiline 1 
mg/day or selegiline 10 mg/day for at least 8 weeks but not more than 8 months and were 
expected to remain on that dose for the duration of the study. The rationale for enrolling 
patients on monoamine oxidase type B inhibitor (MAO-BI) therapy was to reduce the 
number of participants needing additional dopaminergic therapy during the study. Key 
exclusion criteria (the full list is in the appendix) included exposure to other dopaminergic 
Parkinson's disease therapy or amantadine within 60 days before baseline visit or for 90 days 
or more at any point in the past. Patients with diabetes (glycated haemoglobin [HgbA1c] 
≥6% at screening) were excluded. All participants signed a written informed consent before 
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entry into the study. The study was done in accordance with the Good Clinical Practice 
guidelines.
The steering committee developed the protocol and consent forms, and guided the 
implementation of the trial. The protocol and consent forms were approved by a NINDS-
appointed oversight board, an independent data safety monitoring board (DSMB), and the 
institutional review boards of each of the participating sites. The DSMB monitored the 
safety, data integrity, and progress of the trial.
Randomisation and masking
Eligible patients with Parkinson's disease were randomly assigned (1:1:1) to one of three 
study groups: 15 mg/day pioglitazone, 45 mg/day pioglitazone, or placebo. Dose selection 
was based on the preclinical data showing a neuroprotective effect within 15–45 mg/kg 
human dose equivalent11–14 and these doses falling within the FDA-approved range for use 
in the human diabetic population. Participants and investigators were masked to treatment 
group. The Statistical Coordination Center generated the random allocation sequence using a 
permuted block randomisation scheme, and the sites accessed the masked treatment 
assignment via a secure webpage.
Pioglitazone was purchased from the manufacturer (Takeda Pharmaceuticals America, 
Deerfield, IL, USA). University of Iowa Pharmaceuticals over-encapsulated the active 
tablets and created the placebo to match in accordance with current Good Manufacturing 
Practice regulations. The University of Rochester Clinical Materials Services Unit provided 
packaging, labelling, and distribution of the study drug in participant-specific kits. Active 
study drug capsules contained 15 mg pioglitazone. Identical in appearance and taste, placebo 
contained microcrystalline cellulose.
Procedures
At the screening visit, participants had a baseline medical history interview, physical and 
neurological examination, electrocardiogram, UPDRS, and assessments of mood, cognition, 
and disability. Blood and urine were obtained for clinical laboratory tests, a pregnancy test 
for women of childbearing potential, and a test for HgbA1c. Blood and urine samples were 
also collected from consenting participants for measurement of exploratory biomarkers. 
After the baseline visit, participants were reassessed at 2 weeks (within 3 days) by telephone 
and at 4, 16, 28, and 44 weeks (within 5 days) in person.
Study drug was given orally, three capsules once daily. Titration of pioglitazone to 45 
mg/day target dose occurred in 15 mg increments, once every 2 weeks. Dose reduction for 
intolerability was allowed at any point during the study and participants were maintained on 
the highest tolerated dose up to their assigned dose.
Outcomes
The primary outcome was change in total UPDRS score between the baseline visit and 44 
weeks. Data for participants needing additional symptomatic therapy before 44 weeks were 
imputed for the primary analysis, but these participants continued to be followed for 
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secondary analyses. Secondary outcome measures were the change in individual parts of the 
UPDRS, change in ambulatory capacity,21 change in Schwab and England Activities of 
Daily Living (SEADL) scale,22 change in Parkinson's Disease Questionnaire 39 
(PDQ-39),23 change in Mattis Dementia Rating Scale (DRS),24 and change in the Geriatric 
Depression Scale (GDS-15).25 Secondary measures of safety and tolerability were the 
proportion of participants who completed the study on their assigned dose of study drug, the 
adverse event frequency and severity, changes in vital signs, and clinical laboratory values. 
Exploratory outcome measures included the effect of pioglitazone on blood and urine 
biomarkers and the association of concentrations of these biomarkers with change in total 
UPDRS score. Results of the biomarkers analyses will be reported separately. The 
University of Pennsylvania Smell Identification Test (UPSIT) was included in the initial 
protocol as an exploratory measure, but owing to budgetary constraints no UPSIT data were 
collected at follow-up.
Statistical analysis
For each dose group, the primary null hypothesis was that pioglitazone reduces the mean 
UPDRS decline over 44 weeks by 3 points or more compared with placebo. The alternative 
hypothesis (of futility) was that pioglitazone is not meaningfully different from placebo. The 
statistical hypotheses were H0: μ ≤ μp – 3 versus HA: μ > μp – 3, where μ was the expected 
total UPDRS change score from baseline to 44 weeks for the active treatment group and μp 
was the expected placebo total UPDRS change score. If the null hypothesis was rejected at a 
significance level of 0.10, then the drug would be unlikely to be effective and not considered 
for further investigation.
To estimate the sample size, we used the UPDRS change for patients treated with rasagiline 
(1 mg daily) in the controlled trial of efficacy of rasagiline in early Parkinson's disease 
(TEMPO).26 The approximate mean UPDRS change from 8 weeks to 52 weeks (ie, 44 
weeks) was 4.5 (SD 8.0), which provided an estimate of μp and was the rationale for the 44 
week duration of our study. Under the null hypothesis we assumed μ to be μp – 3, which is 
1.5. Under these assumptions (H0: μ=1.5 and HA: μ=4.5), with 65 patients per group, a two-
sample t-test at 0.10 one-sided significance level had 80% power to reject the null 
hypothesis and declare futility if a true difference existed. Assuming a dropout rate of 5%, 
the sample size was inflated from 65 to 72 patients per treatment group.27
Under the intention-to-treat principle all randomly assigned patients were included in the 
primary analyses. Patients who needed additional symptomatic therapy before 44 weeks 
were considered missing primary outcome data. Missing 44 week UPDRS assessments were 
imputed using multiple imputation28 by using all available data for each individual (before 
the add-on of additional symptomatic therapy) and adjusting for the need for additional 
symptomatic therapy (indicator variable), the length of time on rasagiline or selegiline at 
baseline, and treatment group. The multiple imputation procedure assumed a monotone 
missing mechanism, missing at random, and used 20 imputed datasets. The primary analysis 
was adjusted for length of time on rasagiline or selegiline at baseline as a fixed effect and 
enrolling site as a random effect in a mixed-effects linear model. Since this was a phase 2 
study, the type I error rate was relaxed, and there was no correction for multiplicity for the 
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two dose group comparisons. Planned secondary analyses of the primary outcome were last 
value carried forward (LVCF), in which the last observation before additional symptomatic 
therapy was carried forward to 44 weeks, and an analysis of completers, which included 
participants who had a 44 week visit including ones who started additional symptomatic 
therapy. As a post-hoc sensitivity analysis, a mixed-effects model was estimated that 
included the repeated UPDRS measures available for all patients (assuming a first-order 
autoregressive correlation structure for repeated measures) and was adjusted for baseline 
UPDRS, clinical site (as a random effect), and time on rasagiline or selegiline at baseline. 
For the secondary outcomes, the means and 95% CIs were reported by treatment group. A 
non-parametric global statistical test was the prespecified analysis for the secondary 
outcomes, to test whether each active treatment group had less progression compared with 
placebo as measured by SEADL, PDQ-39, ambulatory capacity, and Mattis-DRS. Missing 
data were imputed via multiple imputation. Patients were ranked on each outcome, and then 
the ranks were summed. Higher ranks were worse. The study is registered at 
ClinicalTrials.gov, number NCT01280123.
Role of the funding source
The study sponsor did not participate in the design of the study, but a representative of 
NINDS (D Babcock, NINDS) participated in data interpretation and in the writing of the 
report. NINDS approved the study protocol, had an oversight role in the data collection and 
analysis, and reviewed and approved the decision to submit the paper for publication. All 
authors had full access to all of the data in the study, and TS had responsibility for the final 
decision to submit the report for publication.
Results
Between May 10, 2011, and July 31, 2013, 604 potential participants were identified from 
pre-screening chart review. Of these, 208 were ineligible, 186 declined study participation, 
and the remaining 210 eligible patients were randomly assigned to the three treatment 
groups at 35 sites (figure 1). Baseline demographics and clinical characteristics were similar 
across the three treatment groups except for a difference in GDS-15 (table 1).
The primary analysis suggested that the 45 mg treatment was futile: the mean difference 
between the 45 mg and placebo groups was −1.12 (80% CI −2.93 to 0.69), and we rejected 
the null hypothesis that the 45 mg group was 3 or more points better than the placebo group 
(p=0.09). The primary analysis did not indicate futility for the 15 mg group: the mean 
difference between the 15 mg and placebo groups was −1.83 (80% CI −3.56 to −0.10), and 
the null hypothesis could not be rejected (p=0.19; table 2). Change in UPDRS from baseline 
to week 44 for each treatment group is presented in figure 2. The planned sensitivity 
analyses of the primary outcome suggested that the 15 mg treatment was futile in the last 
value carried forward (p=0.09) and completers only (p=0.09) analyses, and this was 
supported by the post-hoc repeated measures mixed model analyses (p=0.05). The planned 
analyses indicated that the null hypothesis could not be rejected for the 45 mg group (p=0.12 
for the last value carried forward, p=0.19 for the completers) but the post-hoc repeated 
measures mixed model did not (p=0.04; table 2). For secondary efficacy outcomes, the mean 
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changes from baseline to 44 weeks for the treatment groups were similar to placebo (table 
3).
In the non-parametric global statistical test, to assess the change from baseline to 44 weeks 
in SEADL, PDQ-39, ambulatory capacity, and Mattis-DRS, the mean (SD) summed rank 
was 435 (137) for the 15 mg group, 427 (139) for the 45 mg group, and 404 (141) for the 
placebo group (15 mg vs placebo, p=0.20; 45 mg vs placebo, p=0.37).
Of the 210 participants enrolled, 204 (97%) remained in the study for 44 weeks, and 195 
(93%) remained active and on study drug. There were no deaths or treatment unmasking. 
Overall, 30 (14%) participants needed additional symptomatic therapy before 44 weeks 
(nine [13%] in the 15 mg group, 11 [16%] in the 45 mg group, and ten [14%] in the placebo 
group). Missing data occurred owing to the need for additional symptomatic therapy, 
withdrawal of consent, or loss to follow-up; these data were imputed for the total UPDRS at 
44 weeks for 35 (17%) patients (ten in the 15 mg group, 14 in the 45 mg group, and 11 in 
the placebo group). Tolerability, defined as the proportion of the participants taking the 
assigned dose for 44 weeks, was slightly lower in the pioglitazone groups (62 of 72 in the 15 
mg group [86%, 95% CI 78–94], 54 of 67 in the 45 mg group [81%, 71–90], and 67 of 71 in 
the placebo group [94%, 89–100]).
18 patients had serious adverse events. Six occurred in the 15 mg group (ovarian cyst 
ruptured, ankle fracture, atrial flutter, intestinal obstruction, and two cases of intervertebral 
disc protrusion or degeneration). Nine occurred in the 45 mg group (one each of 
spondylolisthesis, osteoarthritis requiring surgery, transient ischaemic attack, dehydration, 
myocardial infarction, intestinal obstruction, and dyspnoea, hypoxia, and respiratory failure, 
and two cases of confusion state). Three occurred in the placebo group (knee replacement, 
atrial fibrillation and hypertension, and coronary artery stenosis). None of the serious 
adverse events was judged as definitely or probably related to the study interventions by the 
masked investigators. The frequency of non-serious adverse events was similar across 
groups: 63 (88%) in the 15 mg group, 51 (76%) in the 45 mg group, and 59 (83%) in the 
placebo group. Expected adverse events included the spectrum of adverse events in the 
diabetic population, as summarised on the package insert. Table 4 shows the most frequently 
occurring adverse events. Cardiovascular events occurred most frequently in the placebo 
group (6% in 15 mg group, 9% in the 45 mg group, 11% in the placebo). Although a 
difference in the proportion of oedema events was detected between all three groups 
(Fisher's exact test, p=0.047), there was no significant pairwise difference versus placebo 
(Fisher's exact test, 45 mg group vs placebo, p=0.35; 15 mg vs placebo, p=0.16). No other 
statistically significant differences were noted.
Weight gain differed by treatment group: the 45 mg group had an adjusted mean increase of 
1.6 kg (SD 2.15), compared with a decrease of −0.25 kg (2.13) for placebo and −0.02 kg 
(2.13) for the 15 mg groups (all adjusted for time). Repeated measures analysis of weight 
change over time indicated a significant difference between treatment groups (F2,207=14.9, 
p<0.0001).
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Monitoring of depression was prespecified in the safety monitoring plan, although no 
specific statistical criteria for stopping were established. Depression as measured by a 
GDS-15 score of 5 or greater occurred more frequently at baseline in the placebo group (2 
[3%] for 15 mg group, 1 [1%] for 45 mg group, and 10 [14%] for placebo), but the mean 
GDS change at 44 weeks was similar by treatment group (table 3). Depressed mood adverse 
events occurred similarly across treatment groups (2 [3%] for 15 mg group, 3 [5%] for 45 
mg group, 3 [4%] for placebo). There were no significant differences in laboratory values by 
treatment group over time or body-mass index (data not shown).
Discussion
Our results suggest that both doses of pioglitazone are unlikely to be effective as 
interventions to slow progression of disability in early Parkinson's disease and we do not 
recommend that they are considered for further study. Although 15 mg pioglitazone was not 
futile in the primary analysis, absence of efficacy on all preplanned sensitivity analyses and 
the secondary outcome measures suggest this dose is futile as well.
Pioglitazone was chosen by the CINAPS panel of experts for testing based on the results of 
well conducted preclinical studies showing reproducible neuroprotective effects in tissue 
culture and animal models.4,29,30 Unfortunately, this is another study in which animal 
models were not predictive of efficacy in human beings. A possible explanation for negative 
outcomes is that toxin animal models are not reflective of Parkinson's disease pathogenesis. 
Another possibility is that pioglitazone failed to reach the target nigral neurons and achieve 
sufficient drug exposure in this study, although good CNS penetration and target 
engagement were shown in primate studies.13
Alternatively, it is possible that the beneficial effect of pioglitazone was missed owing to 
pitfalls of the study design, including the choice of the primary outcome measure. Although 
whether UPDRS is the best outcome measure for the assessment of disease-modifying 
benefit in early Parkinson's disease remains to be proven, it is the best validated measure and 
the one that has extensive data showing its sensitivity to change in early Parkinson's 
disease.31 Consistent findings for all secondary outcomes, which included a spectrum of 
validated measures of quality of life, disability, and cognitive impairment, support an 
absence of biological effect rather than a failure to capture and measure an effect. The 
biomarkers also failed to show a separation of the active treatment groups from placebo and 
as such are concordant with the conclusions drawn from the clinical study (these results will 
be reported separately). If serum and urine biomarkers had shown a shift in the predicted 
direction, then an argument could have been made for a biological effect that was not 
captured by the clinical measures. The finding that both clinical and biological markers 
failed to move is disappointing, but solidifies the conclusion that pioglitazone is not 
promising for further testing in early Parkinson's disease.
Another consideration is the short duration of this and other Parkinson's disease futility 
trials. 1 year or less amounts to a small proportion of the overall clinical course of 
Parkinson's disease. The major objective of futility studies is to screen out quickly 
compounds that do not work. Studies of such short duration might miss important disease-
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modifying effects that could be shown if patients were followed up for longer. Longer 
studies impose a greater burden on patients and higher cost. Ideally, future phase 2 studies of 
disease modification in Parkinson's disease will rely on biomarkers that will increase the 
sensitivity of the analysis over shorter follow-up. Another important consideration for future 
studies is how early Parkinson's disease is defined, as the onset of classic motor symptoms 
might be late biologically. Neuroprotection might not be feasible unless we intervene at the 
premotor stage of the disease. Of the other 12 agents recommended by CINAPS for clinical 
testing, most have entered phase 2 studies and four have completed phase 3 studies. 
Unfortunately, all studies have been negative so far.15,32,33
A novel aspect of this study is that the participants were required to be treated with MAO-BI 
therapy at the time of enrolment. The rationale for this inclusion criterion was to reduce the 
number of patients who would need other dopaminergic treatment during the trial. Untreated 
Parkinson's disease patients are often enrolled to assess short-term (1 year or less) effects of 
a potential disease-modifying drug in exploratory trials. However, nearly half of the 
participants might need dopaminergic therapy before the end of follow-up.34 This poses a 
major problem for the primary analysis because these patients' outcomes have to be carried 
forward from the last observed visit before initiation of dopaminergic therapy, or these data 
must be imputed. Treatment of de novo Parkinson's disease participants with low-dose 
MAO-BI therapy might delay the time to initiation of additional dopaminergic therapy by 
providing symptomatic benefit that might be mild enough to allow for detection of 
improvement due to a study intervention, should one exist. Indeed, only 30 (14%) 
participants needed additional dopaminergic therapy in this study, which is a two-to-three-
fold reduction compared with the previously completed trials in similar populations.34 
MAO-BIs are unlikely to have masked a beneficial effect of pioglitazone because each 
treatment group in this study worsened similarly to those treated with 1 mg rasagiline in the 
TEMPO study,26 which was used to estimate the placebo effect for the power calculations of 
this trial. On the basis of these data we propose to consider enrolment of patients on a stable 
regimen of a mild symptomatic therapy such as MAO-BIs in future phase 2 disease 
modification trials.
Our data show that pioglitazone is unlikely to be efficacious as a disease-modifying 
intervention in early Parkinson's disease and therefore is not recommended for further 
testing for that indication. Although our negative results are disappointing, the design of this 
futility study is an example of a useful and efficient study design that can exclude a 
compound unlikely to be successful in larger and more costly phase 3 studies. 
Unfortunately, as was seen in the recent NET-PD study of creatine,35 even compounds 
deemed non-futile in futility studies might also fail in longer studies. Accordingly, much 
attention has shifted to discovery and validation of biomarkers of disease progression, which 
we hope will accelerate the development of disease-modifying or curative agents.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Page 9
Lancet Neurol. Author manuscript; available in PMC 2016 August 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Acknowledgments
We would like to thank the FS-ZONE participants for their commitment to this study and to Parkinson's disease 
research.
Appendix
Contributors
TS (Principal Investigator) was responsible for study design, study oversight, data 
collection, data analysis, data interpretation, and writing of the final manuscript. KK 
(Principal Investigator, Coordination Center) was responsible for study design, study 
oversight, data interpretation, and critical review of the manuscript. BT (Principal 
Investigator, Statistical Center) was responsible for study design, data analysis, data 
interpretation, and manuscript review. DB was responsible for study design, data 
interpretation, and critical review of the manuscript. JJE was responsible for study design, 
data collection, data analysis, data interpretation, and writing the methods and results 
section. ME was responsible for literature search, study design, data interpretation, and 
critical review of the manuscript. RH, AF, and CS were responsible for data collection, data 
interpretation, and critical review of the manuscript. CK was responsible for study design, 
study drug supply chain management, original grant writing, procurement of funding, data 
collection, and critical review of the manuscript. JCM, GWR, and RBD were responsible for 
study design, data collection, data interpretation, and critical review of the manuscript. BR 
was responsible for study design, study oversight, data collection, data interpretation, and 
critical review of the manuscript. DKS was responsible for study design, data collection, 
data analysis, data interpretation, and critical review of the manuscript. JBa was responsible 
for data collection, data analysis, and critical review of the manuscript. LB, IB-W, JBo, FC, 
JC, KC, CWC, RD, JF, BF, SG, JG, PLB, SLe, ML, MFL, SLo, RP, JS, BSh, KMS, SS, DT, 
RW, AMW, PSW, RZ, and CZ were responsible for data collection and critical review of 
the manuscript. ND was responsible for data collection, review of results, and critical review 
of the manuscript. SLu was responsible for data analysis and critical review of the 
manuscript. AP was responsible for data interpretation, writing, and critical review of the 
manuscript. BSc was responsible for data collection, data interpretation, and critical review 
of the manuscript. KW was responsible for data collection and review of the manuscript.
FS-ZONE Writing Committee
Tanya Simuni MD (Principal Investigator; Northwestern University, Chicago, IL, USA); 
Karl Kieburtz MD (Principal Investigator, Coordination Center; University of Rochester, 
Rochester, NY, USA); Barbara Tilley PhD (Principal Investigator, Statistical Center; 
University of Texas Health Science Center at Houston, Houston, TX, USA); Jordan J Elm 
PhD (Medical University of South Carolina, Charleston, SC, USA); Bernard Ravina MD 
(Voyager Therapeutics, Cambridge, MA, USA); Debra Babcock MD (NINDS, National 
Institutes of Health, Bethesda, MD, USA); Marina Emborg MD (University of Wisconsin, 
Madison, WI, USA); Robert Hauser MD (University of South Florida, Tampa, FL, USA); 
Cornelia Kamp MBA (University of Rochester, Rochester, NY, USA); John C Morgan MD 
(Georgia Regents University, Augusta, GA, USA); G Webster Ross MD (Veterans Affairs 
Page 10
Lancet Neurol. Author manuscript; available in PMC 2016 August 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Pacific Health Care System, Honolulu, HI, USA); David K Simon MD (Beth Israel 
Deaconess Medical Center and Harvard Medical School, Boston, MA, USA); Jacci 
Bainbridge PharmD (University of Colorado Denver, Skaggs School of Pharmacy and 
Pharmaceutical Sciences, Department of Clinical Pharmacy and Neurology, Aurora, CO, 
USA); Liana Baker MPH (University of Rochester, Rochester, NY, USA); Ivan Bodis-
Wollner MD (SUNY Downstate Medical Center, Brooklyn, NY, USA); James Boyd MD 
(University of Vermont, Burlington, VT, USA); Franca Cambi MD (University of 
Kentucky, Lexington, KY, USA); Julie Carter ANP (Oregon Health & Science University, 
Portland, OR, USA); Kelvin Chou MD (Departments of Neurology and Neurosurgery, 
University of Michigan, Ann Arbor, MI, USA); Chadwick W Christine MD (Department of 
Neurology, University of California, San Francisco, San Francisco, CA, USA); Nabila 
Dahodwala MD (University of Pennsylvania, Philadelphia, PA, USA); Richard B Dewey Jr 
MD (University of Texas Southwestern Medical Center, Dallas, TX, USA); Rohit Dhall MD 
(Barrow Neurological Institute, Phoenix, AZ, USA); John Fang MD (Vanderbilt University, 
Nashville, TN, USA); Buff Farrow BS (Georgia Regents University, Augusta, GA, USA); 
Andrew Feigin MD (The Feinstein Institute for Medical Research, North Shore – LIJ Health 
System, Manhasset, NY, USA); Sofya Glazman MD (SUNY Downstate Medical Center, 
Brooklyn, NY, USA); John Goudreau DO (Department of Neurology, Michigan State 
University, East Lansing, MI, USA); Pauline LeBlanc BS (Dartmouth-Hitchcock Medical 
Center, Lebanon, NH, USA); Stephen Lee MD (Dartmouth-Hitchcock Medical Center, 
Lebanon, NH, USA); Maureen Leehey MD (University of Colorado Denver, Aurora, CO, 
USA); Mark F Lew MD (University of Southern California, Los Angeles, CA, USA); 
Stephanie Lowenhaupt RN (University of Virginia, Charlottesville, VA, USA); Sheng Luo 
PhD (The University of Texas Health Science Center at Houston, Houston, TX, USA); 
Rajesh Pahwa MD (University of Kansas Medical Center, Kansas City, KS, USA); Adriana 
Perez PhD (University of Texas Health Science Center at Houston, Austin, TX, USA); Jay 
Schneider PhD (Thomas Jefferson University, Department of Pathology, Anatomy and Cell 
Biology, Philadelphia, PA, USA); Burton Scott MD (Duke University, Durham, NC, USA); 
Binit Shah MD (University of Virginia, Charlottesville, VA, USA); Kathleen M Shannon 
MD (Rush University Medical Center, Chicago, IL, USA); Saloni Sharma MBBS 
(University of Rochester, Rochester, NY, USA); Carlos Singer MD (University of Miami, 
Miami, FL, USA); Daniel Truong MD (Parkinson's & Movement Disorder Institute, 
Fountain Valley, CA, USA); Renee Wagner RN (University of Kentucky, Lexington, KY, 
USA); Karen Williams (Northwestern University, Chicago, IL, USA); Anne Marie Wills 
MD (Brigham & Women's Hospital and Harvard Medical School, Boston, MA, USA); Pei 
Shieen Wong PharmD (University of Colorado Denver, Skaggs School of Pharmacy and 
Pharmaceutical Sciences, Aurora, CO, USA; Singapore General Hospital, Singapore); Cindy 
Zadikoff MD (Northwestern University, Chicago, IL, USA); Richard Zweig MD (LSU 
Health Shreveport, Shreveport, LA, USA).
References
1. de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol. 2006; 5:525–35. 
[PubMed: 16713924] 
2. Suchowersky O, Gronseth G, Perlmutter J, Reich S, Zesiewicz T, Weiner WJ. Practice parameter: 
neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based 
Page 11
Lancet Neurol. Author manuscript; available in PMC 2016 August 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
review): report of the Quality Standards Subcommittee of the American Academy of Neurology. 
Neurology. 2006; 66:976–82. [PubMed: 16606908] 
3. Hart RG, Pearce LA, Ravina BM, Yaltho TC, Marler JR. Neuroprotection trials in Parkinson's 
disease: systematic review. Mov Disord. 2009; 24:647–54. [PubMed: 19117366] 
4. Ravina BM, Fagan SC, Hart RG, et al. Neuroprotective agents for clinical trials in Parkinson's 
disease: a systematic assessment. Neurology. 2003; 60:1234–40. [PubMed: 12707423] 
5. Chaturvedi RK, Beal MF. PPAR: a therapeutic target in Parkinson's disease. J Neurochem. 2008; 
106:506–18. [PubMed: 18384649] 
6. Nicolakakis N, Aboulkassim T, Ongali B, et al. Complete rescue of cerebrovascular function in aged 
Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-
activated receptor gamma agonist. J Neurosci. 2008; 28:9287–96. [PubMed: 18784309] 
7. Risner ME, Saunders AM, Altman JF, et al. Efficacy of rosiglitazone in a genetically defined 
population with mild-to-moderate Alzheimer's disease. Pharmacogenom J. 2006; 6:246–54.
8. Ristow M. Neurodegenerative disorders associated with diabetes mellitus. J Mol Med (Berl). 2004; 
82:510–29. [PubMed: 15175861] 
9. Moreno S, Farioli-Vecchioli S, Ceru MP. Immunolocalization of peroxisome proliferator-activated 
receptors and retinoid X receptors in the adult rat CNS. Neuroscience. 2004; 123:131–45. [PubMed: 
14667448] 
10. Storer PD, Xu J, Chavis J, Drew PD. Peroxisome proliferator-activated receptor-gamma agonists 
inhibit the activation of microglia and astrocytes: implications for multiple sclerosis. J 
Neuroimmunol. 2005; 161:113–22. [PubMed: 15748950] 
11. Eschbach J, von Einem B, Muller K, et al. Mutual exacerbation of peroxisome proliferator-
activated receptor gamma coactivator 1alpha deregulation and alpha-synuclein oligomerization. 
Ann Neurol. 2015; 77:15–32. [PubMed: 25363075] 
12. Swanson C, Emborg M. Expression of peroxisome proliferator-activated receptor-gamma in the 
substantia nigra of hemiparkinsonian nonhuman primates. Neurol Res. 2014; 36:634–46. 
[PubMed: 24620964] 
13. Swanson CR, Joers V, Bondarenko V, et al. The PPAR-gamma agonist pioglitazone modulates 
inflammation and induces neuroprotection in parkinsonian monkeys. J Neuroinflammation. 2011; 
8:91. [PubMed: 21819568] 
14. Dehmer T, Heneka MT, Sastre M, Dichgans J, Schulz JB. Protection by pioglitazone in the MPTP 
model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B 
and iNOS activation. J Neurochem. 2004; 88:494–501. [PubMed: 14690537] 
15. NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and 
minocycline in early Parkinson disease. Neurology. 2006; 66:664–71. [PubMed: 16481597] 
16. NINDS NET-PD Investigators. A randomized clinical trial of coenzyme Q10 and GPI-1485 in 
early Parkinson disease. Neurology. 2007; 68:20–28. [PubMed: 17200487] 
17. Levin B. The utility of futility. Stroke. 2005; 36:2331–32. [PubMed: 16224096] 
18. Tilley BC, Palesch YY, Kieburtz K, et al. Optimizing the ongoing search for new treatments for 
Parkinson disease: using futility designs. Neurology. 2006; 66:628–33. [PubMed: 16534099] 
19. Fahn, S.; Elton, R. UPDRS Development Committee. The Unified Parkinson's Disease Rating 
Scale. In: Fahn, SMC.; Calne, DB.; Goldstein, M., editors. Recent developments in Parkinson's 
disease. Florham Park, NJ: Macmillan Healthcare; 1987. p. 153-64.
20. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic 
Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 
1992; 55:181–84. [PubMed: 1564476] 
21. Parashos SA, Elm J, Boyd JT, et al. Validation of an ambulatory capacity measure in Parkinson 
disease: a construct derived from the unified Parkinson's disease rating scale. J Parkinsons Dis. 
2015; 5:67–73. [PubMed: 25311202] 
22. Schwab, RS.; England, AC, Jr. Projection technique for evaluating surgery in Parkinson's disease. 
In: Gillingham, FJ.; Donaldson, IML., editors. Third symposium on Parkinson's disease. 
Edinburgh: E & S Livingstone; 1969. p. 152-57.
Page 12
Lancet Neurol. Author manuscript; available in PMC 2016 August 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
23. Peto V, Jenkinson C, Fitzpatrick R, Greenhall R. The development and validation of a short 
measure of functioning and well being for individuals with Parkinson's disease. Qual Life Res. 
1995; 4:241–48. [PubMed: 7613534] 
24. Pirogovsky E, Schiehser DM, Litvan I, et al. The utility of the Mattis Dementia Rating Scale in 
Parkinson's disease mild cognitive impairment. Parkinsonism Relat Disord. 2014; 20:627–31. 
[PubMed: 24709086] 
25. Meara J, Mitchelmore E, Hobson P. Use of the GDS-15 geriatric depression scale as a screening 
instrument for depressive symptomatology in patients with Parkinson's disease and their carers in 
the community. Age Ageing. 1999; 28:35–38. [PubMed: 10203202] 
26. Parkinson Study G. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. 
Arch Neurol. 2002; 59:1937–43. [PubMed: 12470183] 
27. Friedman, LFC.; DeMets, D. Fundamentals of clinical trials. 2nd. Littleton, MA: PSG Publishing 
Company; 1985. 
28. Rubin, DB. Multiple Imputation for nonresponse in surveys. New York: John Wiley & Sons; 1987. 
p. 166-67.
29. Pagel-Langenickel I, Bao J, Joseph JJ, et al. PGC-1alpha integrates insulin signaling, 
mitochondrial regulation, and bioenergetic function in skeletal muscle. J Biol Chem. 2008; 283:22 
464–72.
30. Carta AR, Simuni T. Thiazolidinediones under preclinical and early clinical development for the 
treatment of Parkinson's disease. Expert Opin Investig Drugs. 2014; 24:1–9.
31. Parashos SA, Luo S, Biglan KM, et al. Measuring disease progression in early Parkinson disease: 
the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience. 
JAMA Neurol. 2014; 71:710–16. [PubMed: 24711047] 
32. Lang AE, Melamed E, Poewe W, Rascol O. Trial designs used to study neuroprotective therapy in 
Parkinson's disease. Mov Disord. 2013; 28:86–95. [PubMed: 22927060] 
33. Beal MF, Oakes D, Shoulson I, et al. QE3 Investigators. A randomized clinical trial of high-dosage 
coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol. 2014; 71:543–
52. [PubMed: 24664227] 
34. Parashos SA, Swearingen CJ, Biglan KM, et al. Determinants of the timing of symptomatic 
treatment in early Parkinson disease: the National Institutes of Health Exploratory Trials in 
Parkinson Disease (NET-PD) experience. Arch Neurol. 2009; 66:1099–104. [PubMed: 19597081] 
35. Kieburtz K, Tilley BC, Elm JJ, et al. Writing Group for the NINDS Exploratory Trials in Parkinson 
Disease (NET-PD) Investigators. Effect of creatine monohydrate on clinical progression in 
patients with Parkinson disease: a randomized clinical trial. JAMA. 2015; 313:584–93. [PubMed: 
25668262] 
Page 13
Lancet Neurol. Author manuscript; available in PMC 2016 August 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Research in context
Evidence before this study
We searched PubMed for articles published in English before Jan 15, 2015, using the 
terms “Parkinson's disease”, “disease modification”, “clinical trials”, and “pioglitazone”. 
As of that date, no agents had proven to be disease-modifying agents (ie, to slow 
progression) in patients with Parkinson's disease and no studies had assessed the potential 
disease-modifying effects of pioglitazone.
Added value of this study
This is the first randomised controlled trial of pioglitazone, a peroxisome proliferator-
activated receptor γ agonist, as a potential disease-modifying agent in patients with 
Parkinson's disease. The rationale for the choice of study agent was based on the robust 
preclinical data showing a neuroprotective effect in animal models at the doses approved 
for use in human beings. Although the findings of this trial do not warrant further testing 
of pioglitazone in patients with Parkinson's disease, the design of our study could guide 
that of other studies, as we have shown that this design is useful and efficient to exclude a 
compound unlikely to be successful in larger and more costly phase 3 trials.
Implications of all available evidence
These findings suggest that pioglitazone at the doses studied here is unlikely to modify 
progression in early Parkinson's disease. Further study of pioglitazone in a larger trial in 
Parkinson's disease is not recommended, although other peroxisome proliferator-
activated receptor γ agonists might deserve further exploration as disease-modifying 
agents in Parkinson's disease.
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Figure 1. Trial profile
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Figure 2. Change in total Unified Parkinson's Disease Rating Scale (UPDRS) over time by 
treatment group
Means (95% CI) are adjusted for site, time on rasagiline or selegiline at baseline, and 
baseline UPDRS (from repeated measures mixed model). Assessments on participants 
taking additional symptomatic therapy were excluded.
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Table 1
Baseline demographics and clinical characteristics
15 mg pioglitazone (n=72) 45 mg pioglitazone (n=67) Placebo (n=71)
Age (years) 61.3 (10.6) 58.8 (9.2) 59.0 (9.9)
Years of education 17.1 (3.1) 16.2 (3.3) 16.8 (3.0)
Males 53 (74%) 47 (70%) 48 (68%)
Non-latino whites 58 (81%) 63 (94%) 63 (89%)
Right-handed 62 (86%) 62 (93%) 62 (87%)
Duration of PD symptoms (years) 2.3 (1.9) 2.0 (1.2) 2.3 (2.3)
Time since PD diagnosis (years) 0.8 (07) 0.7 (0.7) 0.8 (0.7)
UPDRS total 23.8 (9.9) 21.2 (8.8) 21.7 (8.7)
UPDRS mental 0.8 (0.9) 0.8 (0.9) 0.9 (1.1)
UPDRS motor 17.1 (7.7) 15.0 (7.1) 15.3 (6.5)
UPDRS ADL 5.9 (3.2) 5.5 (2.9) 5.5 (3.0)
Ambulatory capacity 1.1 (0.9) 0.8 (0.8) 1.1 (0.9)
SEADL* 93.8 (4.9) 94.1 (5.0) 93.9 (5.0)
PDQ-39 Summary Index 8.5 (8.1) 8.1 (5.9) 10.6 (7.9)
GDS-15 1.4 (1.4) 1.1 (1.3) 1.8 (1.9)
Mattis-DRS* 138.6 (8.2) 138.8 (10.2) 138.0 (11.4)
Months on rasagiline or selegiline 4.1 (2.2) 4.0 (2.0) 3.7 (1.9)
GDS-15 ≥5 2 (2.8%) 1 (1.5%) 10 (14.1%)
Rasagiline use 60 (83.3%) 57 (85.1%) 60 (84.5%)
Selegiline use 12 (16.7%) 10 (14.9%) 11 (15.5%)
Data are mean (SD) or n (%). UPDRS=Unified Parkinson's Disease Rating Scale. ADL=activities of daily living. SEADL=Schwab and England 
Activities of Daily Living scale. PDQ-39=Parkinson's Disease Questionnaire 39. GDS-15=15-item Geriatric Depression Scale. DRS=Dementia 
Rating Scale.
*
Higher scores are associated with less severe clinical presentation; for all other clinical symptoms, higher scores are associated with more severe 
presentation.
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Table 3
Secondary outcomes: change from baseline to 44 weeks
15 mg pioglitazone (n=72) 45 mg pioglitazone (n=67) Placebo (n=71)
UPDRS mental 0.10 (−0.16 to 0.36) 0.09 (−0.18 to 0.36) 0.18 (−0.13 to 0.49)
UPDRS motor 3.12 (1.79 to 4.46) 3.10 (1.29 to 4.90) 3.86 (2.47 to 5.26)
UPDRS ADL 1.44 (0.76 to 2.12) 1.44 (0.72 to 2.17) 1.73 (0.9 to 2.56)
Ambulatory capacity 0.39 (0.16 to 0.61) 0.38 (0.07 to 0.70) 0.40 (0.17 to 0.64)
SEADL* −2.12 (−3.47 to −0.78) −2.52 (−3.95 to −1.09) −1.84 (−3.49 to −0.18)
PDQ-39 Summary Index 2.03 (0.47 to 3.59) 2.08 (0.32 to 3.84) 0.08 (−1.59 to 1.76)
GDS-15 0.13 (−0.33 to 0.58) 0.38 (−0.10 to 0.85) 0.18 (−0.37 to 0.72)
Mattis-DRS* 1.16 (−1.26 to 3.58) 2.11 (−0.41 to 4.63) 3.16 (0.66 to 5.65)
Data are mean (95% CI). Secondary outcomes analyses include all patients enrolled and are change from baseline to 44 weeks. Missing data 
imputed with multiple imputation. Means are adjusted for site. UPDRS=Unified Parkinson's Disease Rating Scale. ADL=activities of daily living. 
SEADL=Schwab and England Activities of Daily Living scale. PDQ-39=Parkinson's Disease Questionnaire 39. GDS=Geriatric Depression Scale. 
DRS=Dementia Rating Scale.
*
Higher scores are associated with less severe clinical presentation; for all other clinical symptoms, higher scores are associated with more severe 
presentation.
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Table 4
Frequently occurring adverse events
Placebo 15 mg pioglitazone 45 mg pioglitazone Total
Oedema 9 (13%) 4 (6%) 13 (19%) 26 (12%)
Cardiovascular events 8 (11%) 4 (6%) 6 (9%) 18 (9%)
Diarrhoea 3 (4%) 7 (10%) 3 (4%) 13 (6%)
Nausea 3 (4%) 6 (8%) 7 (10%) 16 (8%)
Raised blood creatine phosphokinase 11 (15%) 12 (17%) 7 (10%) 30 (14%)
Dizziness 6 (8%) 5 (7%) 6 (9%) 17 (8%)
Fatigue 3 (4%) 8 (11%) 2 (3%) 13 (6%)
Data are n (%) of patients.
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